Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of DA-1229_01 in Healthy Subjects at Fed State
NCT07342062Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Jan 2026
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 24 hours and Maximum Plasma Concentration at 24 hours. Started Jan 2026; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07342062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342062.